{"log_id": 165165108916198624, "direction": 0, "words_result_num": 43, "words_result": [{"probability": {"variance": 0.006561, "average": 0.977184, "min": 0.526516}, "location": {"width": 674, "top": 232, "height": 26, "left": 288}, "words": "表15.富马酸替诺福韦二吡呋酯各项HBV治疗试验中病毒血症受试者氨基酸突变"}, {"probability": {"variance": 0.000355, "average": 0.986031, "min": 0.950768}, "location": {"width": 93, "top": 274, "height": 23, "left": 599}, "words": "代偿性肝病"}, {"probability": {"variance": 0.004929, "average": 0.977217, "min": 0.678712}, "location": {"width": 579, "top": 313, "height": 25, "left": 443}, "words": "核苷初治者阿德福韦经治者拉米夫定耐药者失代偿性肝病"}, {"probability": {"variance": 0.000354, "average": 0.986308, "min": 0.946272}, "location": {"width": 62, "top": 355, "height": 17, "left": 456}, "words": "(N=659)"}, {"probability": {"variance": 5e-05, "average": 0.992565, "min": 0.980859}, "location": {"width": 57, "top": 354, "height": 19, "left": 618}, "words": "(N=247"}, {"probability": {"variance": 0.000784, "average": 0.979198, "min": 0.917209}, "location": {"width": 64, "top": 355, "height": 17, "left": 771}, "words": "(N=136"}, {"probability": {"variance": 5.8e-05, "average": 0.994116, "min": 0.980988}, "location": {"width": 40, "top": 355, "height": 17, "left": 941}, "words": "N=39"}, {"probability": {"variance": 0.000903, "average": 0.982693, "min": 0.899799}, "location": {"width": 168, "top": 390, "height": 24, "left": 212}, "words": "富马酸替诺福韦二吡"}, {"probability": {"variance": 0.000322, "average": 0.99313, "min": 0.942411}, "location": {"width": 166, "top": 427, "height": 23, "left": 214}, "words": "呋酯治疗末次时间点"}, {"probability": {"variance": 0.001307, "average": 0.98314, "min": 0.875338}, "location": {"width": 101, "top": 429, "height": 19, "left": 598}, "words": "34/247(14%"}, {"probability": {"variance": 0.006192, "average": 0.960218, "min": 0.741489}, "location": {"width": 81, "top": 429, "height": 20, "left": 766}, "words": "9/136(7%)"}, {"probability": {"variance": 8.8e-05, "average": 0.987111, "min": 0.9705}, "location": {"width": 64, "top": 428, "height": 20, "left": 918}, "words": "7/39(1"}, {"probability": {"variance": 0.000238, "average": 0.988592, "min": 0.956756}, "location": {"width": 53, "top": 447, "height": 18, "left": 436}, "words": "60/659"}, {"probability": {"variance": 1e-06, "average": 0.99855, "min": 0.996785}, "location": {"width": 130, "top": 463, "height": 24, "left": 212}, "words": "时存在病毒血症"}, {"probability": {"variance": 0.026401, "average": 0.931988, "min": 0.47844}, "location": {"width": 162, "top": 501, "height": 22, "left": 219}, "words": "治疗引发的氨基酸突"}, {"probability": {"variance": 0.000199, "average": 0.984593, "min": 0.952029}, "location": {"width": 94, "top": 519, "height": 22, "left": 440}, "words": "20/44(45%)"}, {"probability": {"variance": 0.002799, "average": 0.972105, "min": 0.85409}, "location": {"width": 71, "top": 520, "height": 21, "left": 599}, "words": "0/27(3"}, {"probability": {"variance": 0.000268, "average": 0.988908, "min": 0.946687}, "location": {"width": 81, "top": 522, "height": 19, "left": 922}, "words": "3/5(60%)"}, {"probability": {"variance": 0, "average": 0.999938, "min": 0.999938}, "location": {"width": 21, "top": 538, "height": 20, "left": 214}, "words": "变"}, {"probability": {"variance": 0.000827, "average": 0.977077, "min": 0.909475}, "location": {"width": 76, "top": 538, "height": 19, "left": 766}, "words": "6/8(75%)"}, {"probability": {"variance": 0.00502, "average": 0.965218, "min": 0.62372}, "location": {"width": 724, "top": 573, "height": 24, "left": 248}, "words": "研究0102(N246)、0103(N=171)接受富马酸替诺韦二吡呋酯达240周的核苷初治受试者。研究"}, {"probability": {"variance": 0.011924, "average": 0.958433, "min": 0.480661}, "location": {"width": 272, "top": 607, "height": 21, "left": 246}, "words": "L0C114648(N=242)治疗48周的数据"}, {"probability": {"variance": 0.003905, "average": 0.972909, "min": 0.637047}, "location": {"width": 779, "top": 640, "height": 24, "left": 247}, "words": "研究0102/0103(N=195)和0106(N=52)中阿德福韦酯经治、在将阿德福韦酯换为富马酸替诺福韦二吡呋酯"}, {"probability": {"variance": 0.006979, "average": 0.975971, "min": 0.55914}, "location": {"width": 781, "top": 673, "height": 21, "left": 244}, "words": "后接受富马酸替诺福韦二吡呋酯治疗达192周受试者。研究0106是一项己完成的为期168周的随机、双育2"}, {"probability": {"variance": 2.7e-05, "average": 0.995643, "min": 0.988299}, "location": {"width": 45, "top": 706, "height": 20, "left": 248}, "words": "期试验"}, {"probability": {"variance": 0.007413, "average": 0.96719, "min": 0.593567}, "location": {"width": 784, "top": 738, "height": 22, "left": 245}, "words": "研究0121(N=136)中拉米夫定耐药受试者从拉米夫定换成富马酸替诺福韦二吡呋酯后接受富马酸替诺福韦二吡"}, {"probability": {"variance": 0.030814, "average": 0.92697, "min": 0.463233}, "location": {"width": 130, "top": 769, "height": 20, "left": 244}, "words": "呋酯治疗达96周"}, {"probability": {"variance": 0.008734, "average": 0.970387, "min": 0.519189}, "location": {"width": 656, "top": 802, "height": 23, "left": 245}, "words": "研究0108中患有失代偿期肝病、接受富马酸替诺福韦二吡呋酯治疗达48周的受试者(N=39"}, {"probability": {"variance": 0.005185, "average": 0.981028, "min": 0.569287}, "location": {"width": 795, "top": 833, "height": 22, "left": 245}, "words": "分母包括富马酸替诺福韦二吡呋酯单药治疗末次时间点时患有病毒血症并且具有可评价的配对基因型数据受试"}, {"probability": {"variance": 0.001933, "average": 0.98708, "min": 0.695646}, "location": {"width": 789, "top": 897, "height": 25, "left": 245}, "words": "19例受试者在研究0102和0103中治疗期间出现的氨基酸突变,其中5例受试者出现保守位点变化14例受"}, {"probability": {"variance": 0.004145, "average": 0.985195, "min": 0.580977}, "location": {"width": 684, "top": 929, "height": 23, "left": 245}, "words": "试者仅出现多态位点变化,8例受试者为一过性突变其突变在末次治疗时间点未能检测出。研究"}, {"probability": {"variance": 0.000505, "average": 0.976404, "min": 0.953926}, "location": {"width": 15, "top": 934, "height": 17, "left": 993}, "words": "48"}, {"probability": {"variance": 0.005837, "average": 0.974082, "min": 0.699699}, "location": {"width": 453, "top": 963, "height": 22, "left": 244}, "words": "仅1例受试者富马酸替诺福韦二吡呋酯治疗48周期间出现突变"}, {"probability": {"variance": 0.006807, "average": 0.971091, "min": 0.554576}, "location": {"width": 789, "top": 995, "height": 23, "left": 245}, "words": "10名阿德福韦经治受试者出现治疗期间出现氨基酸突变,2例受试者出现保守位点变化,其中8名仅出现多态"}, {"probability": {"variance": 0, "average": 0.99897, "min": 0.998536}, "location": {"width": 70, "top": 1025, "height": 22, "left": 243}, "words": "位点变化"}, {"probability": {"variance": 0.000931, "average": 0.991517, "min": 0.784259}, "location": {"width": 793, "top": 1060, "height": 22, "left": 233}, "words": "6名拉米夫定耐药受试者在研究0121治疗期间出现的氨基酸突变,其中3例受试者仅出现多态位点变化,3例"}, {"probability": {"variance": 0, "average": 0.999144, "min": 0.998244}, "location": {"width": 179, "top": 1092, "height": 18, "left": 245}, "words": "受试者出现保守位点变化"}, {"probability": {"variance": 0.000423, "average": 0.993611, "min": 0.885555}, "location": {"width": 713, "top": 1164, "height": 29, "left": 254}, "words": "交叉耐药:在HBV核苷/核苷酸类似物逆转录酶抑制剂之间观察到交叉耐药"}, {"probability": {"variance": 0.004359, "average": 0.969994, "min": 0.617923}, "location": {"width": 780, "top": 1206, "height": 28, "left": 254}, "words": "基于细胞试验,拉米夫定和替比夫定耐药相关rtV173L、rtL180M和rtM204I/V突"}, {"probability": {"variance": 0.004281, "average": 0.977945, "min": 0.635772}, "location": {"width": 761, "top": 1249, "height": 27, "left": 212}, "words": "变的HBV病毒株对替诺福韦的敏感性为野生型病毒的0.7至3.4倍。rtL180M和"}, {"probability": {"variance": 0.000249, "average": 0.99232, "min": 0.931373}, "location": {"width": 480, "top": 1292, "height": 27, "left": 231}, "words": "M204I/V双突变后对替诺福韦的敏感性降低3.4倍"}, {"probability": {"variance": 0.008976, "average": 0.959158, "min": 0.58752}, "location": {"width": 783, "top": 1335, "height": 26, "left": 255}, "words": "恩替卡韦耐药相关rtL180M、rtT184G、rtS202G/I、rtM204V和rtM250V突变的"}, {"probability": {"variance": 0.000685, "average": 0.993676, "min": 0.855203}, "location": {"width": 584, "top": 1377, "height": 26, "left": 213}, "words": "HBV病毒株对替诺福韦的敏感性为野生型病毒的0.6至6.9倍"}], "language": 3}